Immunomodulation of asthma: where do we stand?
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D006967:Hypersensitivity / Q000235:genetics / Q000276:immunology / Q000628:therapy; D007073:Immunoglobulin E / Q000276:immunology; D000069444:Omalizumab; D018123:Receptors, Interleukin / Q000037:antagonists & inhibitors; D019444:Vaccines, DNA / Q000627:therapeutic use
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D018123:Receptors, Interleukin; D019444:Vaccines, DNA; D000069444:Omalizumab; D007073:Immunoglobulin E